<DOC>
	<DOCNO>NCT02459834</DOCNO>
	<brief_summary>Diabetes remain one important unmet prevention treatment challenge , prevalence diabetes continue grow . Some functional food ingredient may hold promise potential therapy diabetes . One functional food allulose , c-3 epimer fructose . Allulose non-caloric sugar find naturally small amount food dry fruit , brown sugar maple syrup . Previous research find catalytic dos fructose allulose show decrease postprandial glycemic response high glycemic index meal . Fructose , exchange carbohydrate , also find decrease HbA1c level . Whether effect fructose allulose equivalent particular interest , allulose represent non-caloric alternative fructose . The minimum 'catalytic ' dose improvement carbohydrate metabolism observe also remain determined sugar people without diabetes . This study acute randomize controlled dose-finding equivalence trial ass effect fructose allulose 2 dose level ( 5g 10g ) compare control ( 0g ) glucose insulin responses 75g oral glucose tolerance test ( OGTT ) healthy type 2 diabetes participant .</brief_summary>
	<brief_title>The Fructose Allulose Catalytic Effects ( FACE ) Trial</brief_title>
	<detailed_description>Diabetes remain one important unmet prevention treatment challenge . Despite grow armamentarium medication , include six new class drug since metformin first approve 1995 US , combine prevalence impair glucose tolerance ( IGT ) diabetes continue grow . Although oral antihyperglycaemic agent show prevent development diabetes high-risk individual reduce risk microvascular complication individual type 2 diabetes , fail deliver anticipate macrovascular benefit . Some functional food ingredient may hold promise potential therapy diabetes . An emerge literature show low-dose fructose c-3 epimer , allulose ( non-caloric sugar find naturally small amount food dry fruit , brown sugar , maple syrup generally recognize safe [ GRAS ] FDA GRN 400 since 2012 GRN 498 since 2014 ) may benefit glycemic control . Clinical translation finding proven promise . Catalytic dos fructose 7.5g 10g allulose 5g , 7.5g , 10g ( 2.5g ) show decrease postprandial glycemic response high glycemic index meal ( oral glucose , maltodextrins , mash potato ) ~15-30 % healthy participant prediabetes diabetes . These acute effect show sustainable long term case fructose . In separate systematic review meta-analyses control feeding trial , investigator show small dos ( define ≤36g/day base 3 meal ≤10g/meal 2 snack ≤3g/snack ) high dos ( median , 60g/day ) fructose exchange carbohydrate decrease HbA1c 0.4 % 0.53 % , respectively , level reduction exceed clinically meaningful threshold 0.3 % propose Federal Drug Administration ( FDA ) development new oral anti-hyperglycemic agent . Although finding provide compel proof concept , urgent need replication study . Whether effect fructose allulose equivalent particular interest , allulose represent non-caloric alternative fructose . The minimum 'catalytic ' dose improvement carbohydrate metabolism observe also remain determined sugar people without diabetes . OBJECTIVES - To assess acute catalytic effect fructose allulose 2 dose level ( 5g , 10g ) compare control ( 0g ) glucose insulin responses 75g oral glucose tolerance test ( 75g-OGTT ) healthy participant participant type 2 diabetes . - To assess whether dose response threshold propose dose range ( 0g , 5g , 10g ) effect fructose allulose glucose insulin response 75g-OGTT healthy participant participant type 2 diabetes . - To assess whether effect allulose fructose equivalent/non-inferior primary endpoint incremental area curve ( iAUC ) plasma glucose across 2 dose level ( 5g 10g ) compare control ( 0g ) healthy participant participant type 2 diabetes .</detailed_description>
	<criteria>Healthy participant : Adult male nonpregnant female Normal weight Nonsmokers Free disease illness Do regular take medication Have primary care physician Diabetes participant : Wellcontrolled diabetes diet and/or oral antihyperglycemic agent Not take insulin Free major illness Have primary care physician Healthy participant : Age &lt; 18 &gt; 75y , Pregnant female Regular medication use Complementary alternative medicine ( CAM ) use BMI &lt; 18.5kg/m2 , &gt; 30kg/m2 Prediabetes diabetes ( HbA1c≥6 % , FBG≥6.1mmol/L ) Hypertension ( BP≥140/90 ) , Dyslipidemia ( Canadian Cardiovascular Society guideline ) Metabolic syndrome ( harmonized definition ) Polycystic ovarian syndrome Cardiovascular disease Gastrointestinal disease Previous bariatric surgery Liver disease ( abnormal liver enzyme ) Hyperthyroidism ( abnormal TSH ) Hypothyroidism ( abnormal TSH ) Nephropathy ( albumintocreatinine ratio [ ACR ] &gt; 20 ) Chronic kidney disease ( eGFR &gt; 60ml/min/1.73m2 ) Inflammatory condition ( CRP &gt; 3g/L ) Acute chronic infection ( abnormal white blood cell count ( WBC ) , CRP &gt; 3g/L ) Anemia ( abnormal Hb ) Lung disease Cancer/malignancy Psychiatric illness Major surgery last 6 month Other major illness Smoker Heavy alcohol use ( &gt; 3 drinks/day ) Diabetes participant : Age &lt; 18 &gt; 75y Pregnant female Poorly control diabetes ( HbA1c &gt; 7 % ) Recent diabetes medication change ( &lt; 3 month ) Insulin use Complementary alternative medicine ( CAM ) use BMI &lt; 18.5kg/m2 , ≥35kg/m2 Cardiovascular disease Retinopathy Neuropathy Diabetic foot Gastrointestinal disease Previous bariatric surgery Liver disease ( abnormal liver enzyme ) Hyperthyroidism ( abnormal TSH ) Hypothyroidism ( abnormal TSH ) Anemia ( abnormal Hb ) Nephropathy ( albumintocreatinine ratio [ ACR ] &gt; 20 ) Chronic kidney disease ( eGFR &gt; 60ml/min/1.73m2 ) Inflammatory condition ( CRP &gt; 3g/L ) Acute chronic infection ( abnormal WBC , CRP &gt; 3g/L ) Lung disease Cancer/malignancy Psychiatric illness Major surgery last 6 month Other major illness Smoker Heavy alcohol use ( &gt; 3 drinks/day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Allulose</keyword>
	<keyword>Fructose</keyword>
	<keyword>Dose Response</keyword>
	<keyword>Catalytic Dose</keyword>
	<keyword>Carbohydrate metabolism</keyword>
	<keyword>Randomized clinical trial</keyword>
</DOC>